Wednesday, October 27, 2021

J&J won’t pursue Erleada, Zytiga prostate cancer combo after trial results disappoint

Johnson & Johnson won’t file regulatory submissions for its prostate cancer combo of Erleada and Zytiga after the pair failed to reach key secondary trial goals, including overall patient survival. 

The New Jersey drug giant based its decision on findings from the combo’s phase 3 ACIS study, which were presented at the American Society of Clinical Oncology’s Genitourinary Cancers Symposium in February.

The trial tested J&J’s androgen receptor inhibitor Erleada with its aging prostate cancer med Zytiga and corticosteroid prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer. The patients had previously received androgen deprivation therapy. 

The trial met its primary endpoint, showing the three-drug combo reduced the risk of radiographic progression or death in patients by 31% over Zytiga and prednisone. But it failed to show “significant benefit” in key secondary endpoints, including life extension, time to chronic opioid use, time to initiation of cytotoxic chemotherapy, and time to pain progression, J&J said.

RELATED: ASCO: J&J’s Erleada extends lives by 14 months in nonmetastatic prostate cancer

Not all is lost, J&J says. The study generated “valuable scientific outcomes and insights in subgroups of patients” which warrant further investigation, Janssen’s Kiran Patel, vice president of clinical development, solid tumors, said in a statement.

“These data will be important in informing future programs in our pipeline, as we look to build upon our leadership and commitment in bringing transformational therapies to patients diagnosed with prostate cancer,” Patel added.

After generics launched in late 2018, copycats have been weighing on revenues for J&J’s Zytiga. The med generated $50 million in U.S. sales during the first quarter, J&J reported Tuesday, a 64% drop compared with the same quarter last year. 

RELATED: Fighting for market share, J&J expects last year’s copycat pain to ‘bleed into 2020’

Meanwhile, sales for Erleada are on the rise. The company reported that U.S. sales of Erleada reached $171 million in the first quarter, a 44% increase compared with the same period last year.

Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...